The genome editing market size reached US$ 8.03 billion in 2023 and is projected to grow to around US$ 38.43 billion by 2033, with a CAGR of 16.95% during the forecast period from 2024 to 2033.
The genome editing market size reached US$ 8.03 billion in 2023 and is projected to grow to around US$ 38.43 billion by 2033, with a CAGR of 16.95% during the forecast period from 2024 to 2033. Genome editing has diverse applications in several sectors such as medicine and agriculture which will likely lead to robust growth in the market during the forecast period.
Download a sample version of genome editing market segmental and competitive analysis report (in detail TOC available) @ https://www.towardshealthcare.com/personalized-scope/5161
Key Takeaways
- North America leads the gene editing market with the dominating share.
- Asia-Pacific is expected to be the fastest-growing region during the forecast period.
- By application, genetic engineering accounted for the largest share in 2023
- By technology, CRISPR/Cas9 remains the most popular with the dominating share in the market.
Genome Editing Market at a Glance
Genome editing, also known as gene editing, is a branch of scientific research that deals with understanding and modifying segments of DNA in organisms to change functions and expression. Gene editing can be used to correct, introduce, or remove DNA sequences in different cells of plants, animals, and microorganisms. Genome editing harnesses a natural process of DNA repair. Breaking a section of DNA prompts the cell’s repair mechanism to stitch the break.
Genome editing technology is used to treat acquired and hereditary diseases in humans. Genome editing is also being used to increase plant resistance to diseases, and harsh weather, and increase their nutritional value. Gene editing technology has applications across sectors such as medicine, agriculture and biotechnology. The sector holds potential in disease diagnosis and prevention, therapeutic development for conditions from being passed on in humans and animals, genetically modifying plants and animals and drug discoveries.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Top Companies in the Genome Editing Market
- Thermo Fisher Scientific, Inc
- Lonza
- Bluebird Bio, Inc.
- OriGene Technologies, Inc.
- New England Biolabs
- Genscript Biotech Corp
- Transposagen Biopharmaceuticals, Inc.
- Danaher Corporation
- Horizon Discovery Ltd. (Revvity, Inc.)
- Takara Bio Inc.
- AstraZeneca
- Cellectis S.A.
- Caribou Biosciences, Inc
- Intellia Therapeutics, Inc.
- CRISPR Therapeutics
- Precision BioSciences
- Editas Medicine
- Sangamo Therapeutics
- Recombinetics
- Cibus Inc.
- Merck KGaA
Versatile Gene Editing Technologies and Diverse Applications
The last decade has seen the development of three foundational gene editing technologies clustered regularly interspaced short palindromic repeats and associated protein 9 (CRISPR-Cas9), transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs). These technologies can make precise modifications in a wide variety of cell types quickly and at a lower cost than before. Advancements in the technology ensure lower genomic screening times, and a reduction in off-target effects, improving overall efficacy.
Gene editing has applications across industries like disease diagnostics and gene therapies with the possibility of correcting mutations to cure existing conditions and making genetic alterations that will be passed on to subsequent generations. These innovations are fueling growth in the gene editing sector by solving issues related to time, cost, and precision, further expanding therapeutic applications in clinically relevant areas.
Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5161
Challenges with Long-term Stable Expression in Genomes and High End-user Cost
Gene editing tools currently rely on transient expression in cells to mitigate risks of off-target DNA cleavage, where an incorrect DNA sequence is edited, resulting in toxicity and oncogenicity from the modifications. Techniques such as off-target identification, sgRNA optimization, prime editing, and others, need to be streamlined to reduce off-targeting risks.
While the relative costs of gene editing technologies continue to fall, the end-user experience remains prohibitively expensive, posing significant barriers to widespread adoption. These financial barriers hinder the growth of the gene editing sector, with further innovations needed to increase accessibility.
Potential Applications in Treating Genetic Disorders and Off-targeting Mitigation
Gene editing is seen as a promising way to develop therapies to treat genetic disorders which affect about 2%-5% of all live births and account for up to 30% of pediatric hospital admissions. Gene therapies can be used to treat inherited disorders or diseases that lower life expectancy by replacing the damaged genes. Currently, only around 5% of rare genetic illnesses have effective therapies.
Advancements in cellular assays, protein engineering, and novel NGS methods can mitigate issues with detecting structural variants and off-targeting.
How North America Sustains as an Ever-growing Marketplace for Genome Editing?
North America has the largest market share in the genome editing market, accounting for 48% in 2023. The region has pioneered research and development in gene editing and related therapies. The technology enjoys strong public support in the region which is increasingly receptive to therapeutic applications in treating genetic blood disorders like sickle cell anemia and beta-thalassemia. There is public awareness and acceptance of GMOs or genetically modified organisms, which are regulated by three federal entities; the U.S. Department of Agriculture (USDA), the Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA).
- In March 2024, Intellia Therapeutics dosed the first patient in a pivotal trial of its in vivo CRISPR candidate NTLA-2001 to treat patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) using one-time gene editing treatment.
Asia Pacific to Grow at the Fastest Rate in the Upcoming Period
Asia Pacific is expected to grow the fastest during the forecast period with the fastest CAGR owing to gene-editing applications in agriculture. With more than half the world’s population located in the region, there is pressure to develop high-nutrition, disease-resistant crops. The genome editing market is growing due to countries like China, India, and South Korea which are investing in gene editing technologies to achieve food security and promote sustainable agricultural practices. Academic and research institutions in countries like China, Japan, and South Korea are actively engaged in genome editing research to understand genetic mechanisms and develop new therapies. Genome editing holds promise for treating genetic disorders and diseases more effectively. Asian countries are exploring applications in personalized medicine and therapeutic treatments.
The Genetic Engineering Segment to Sustain as a Leader
By application, the genetic engineering segment accounted for the largest segment in the genome editing market for 2023. Genetic engineering plays a pivotal role in the development of genetically modified crops and animals. It has applications in the production of medicine and vaccines. Genetic engineering is relatively simple and cost-effective compared to older genome editing methods like zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). This accessibility has accelerated research in genetics and molecular biology.
The CRISPR/Cas9 Technologies to Promote the Market’s Expansion
CRISPR allows scientists to precisely target specific sequences of DNA within the genome. This precision enables accurate editing of genes, facilitating the study of gene function and potential therapeutic applications. CRISPR-Cas systems have high efficiency in editing genomes compared to earlier gene-editing techniques. This efficiency reduces the time and resources needed for genetic modification experiments.
Major Breakthroughs in Genome Editing Market:
- In May 2024, German multinational pharmaceutical Bayer and South Korean biotech company G+FLAS agreed to collaborate on developing genome-edited tomato varieties that are nutritionally enhanced with vitamin D3. Bayer also acquired a license from Pairwise that grants rights to work with and commercialize Pairwise’s genome-edited green leafy vegetables.
- In April 2024, US-based startup Profluent released the first open-source AI-generated gene editor. Profluent is developing deep generative models to design and validate novel, functional proteins as part of the OpenCRISPRTM project. Using Profluent’s large language models (LLMs), OpenCRISPR-1 is an AI-generated gene editor that consists of a guide RNA and a Cas9-like protein.
- In February 2024, a new, precision-targeted delivery method for CRISPR-Cas9 was demonstrated to enable gene editing in specific types of human T-cells. The development of this method is a step toward in vivo gene editing.
Browse More Insights of Towards Healthcare:
- The global atrial fibrillation treatment market size was valued at $ 23.06 billion in 2023 to reach $ 37.42 billion by 2033, expanding at a 5.2% of CAGR between 2023 and 2033.
- The global synovial sarcoma treatment market size surpassed $ 822.74 million in 2023 to hit around $ 1144.84 million by 2033, growing at a 3.6% CAGR between 2023 and 2033.
- The global rheumatoid arthritis drugs market size reached a value of USD 17.87 billion in 2023 and is projected to grow to USD 27.38 billion by 2033, suggests with a CAGR of 4.6% from 2023 to 2033.
- The global hemato-oncology testing market size was valued at USD 3.17 billion in 2023 and is expected to reach USD 9.78 billion by 2033, indicating at a CAGR of 12.4% from 2024 to 2033.
- The global autoimmune hepatitis diagnosis and treatment market size to increase from USD 14.03 billion in 2023 to exceed USD 19.15 billion by 2032, growing at a CAGR of 3.3% between 2023 and 2032.
- The global bone densitometer market size was worth USD 308.33 million in 2023 and is expected to reach USD 466.83 million by 2032, projecting at a CAGR of 4.3% from 2024 to 2032.
- The global vein finder market size to increase from USD 49.15 million in 2023 to exceed approximately USD 113.24 million by 2032, expanding at a CAGR of 8.7% between 2024 and 2032.
- The global newborn screening market size is projected to expand from USD 3.23 billion in 2023 to reach USD 5.96 billion by 2032, increasing at a CAGR of 6.5% between 2024 and 2032.
- The nanomedicine market reached a value of $219.34 billion in 2023 and is expected to hit $562.93 billion by 2032, showing a CAGR of 10.1% from 2024 to 2032.
- The weight management market is to climb from USD 150.63 billion in 2023 to approximately USD 328.24 billion by 2032, with a CAGR of 8.3% from 2024 to 2032.
Segments Covered in Genome Editing Market Report
By Application
- Genetic Engineering
- Cell Line Engineering
- Animal Genetic Engineering
- Plant Genetic Engineering
- Others
- Clinical Applications
- Diagnostics
- Therapy Development
By Technology
- (CRISPR)/Cas9
- TALENs/MegaTALs
- ZFN
- Meganuclease
- Others
By Delivery Method
- Ex-vivo
- In-vivo
By End-use
- Biotechnology and Pharmaceutical Companies
- Academic and Government Research Institutes
- Contract Research Organizations
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5161
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Browse our Brand-New Journals:
https://www.towardspackaging.com
https://www.towardsautomotive.com
https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com
